Shen-Yen Lin1,2, Chien-Ming Chen1,2, Bing-Shen Huang2,3, Ying-Chieh Lai1,2, Kuang-Tse Pan1,2, Shi-Ming Lin2,4, Sung-Yu Chu1,2, Jeng-Hwei Tseng1,2. 1. Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. 2. College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Department of Radiation Oncology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan. 4. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Abstract
PURPOSE: To demonstrate the feasibility of magnetic resonance imaging (MRI) for early prediction of proton beam therapy (PBT) effectiveness in hepatocellular carcinoma (HCC). METHODS: Clinical data of the HCC patients without regional lymph node involvement or distant metastasis who received PBT at this institution between 2014 and 2017 were reviewed. A total of 43 patients were included. Tumor regression pattern after PBT were examined on the basis of follow-up duration. The variables were compared between patients with and without early tumor regression (ETR). RESULTS: The median follow-up duration was 40 months (range, 9-62 months). The cumulative overall survival rate at 6 months, 1 years and 5 years was 100%, 88.4%, 63.4%, respectively. Child-Pugh class A, local tumor control (LTC), complete response (CR), and ETR were significantly associated with overall survival (p < 0.05 each). Of 43 patients, 25 patients (58.1%) reached CR in the PBT-irradiated region. Twelve patients (27.9%) had a partial response and 3 patients (7.0%) had a stationary disease. Three patients (7.0%) developed in-field progression. The LTC rate at 5 years was 93.0%. Of the 25 patients who achieved a CR in the PBT-irradiated region, the median time to CR was 5 months (range, 1-19 months). Twenty-two patients (51.2%) showed ETR of the HCC, while 21 patients (48.8%) showed non-ETR. A significant association was observed between ETR and CR of the HCC after PBT (p < 0.001). CONCLUSION: The post-PBT MRI follow-up at 3 months is helpful for monitoring therapeutic response. ETR of the HCC predicted a higher rate of CR and was associated with overall survival, which provides more accurate clinical management.
PURPOSE: To demonstrate the feasibility of magnetic resonance imaging (MRI) for early prediction of proton beam therapy (PBT) effectiveness in hepatocellular carcinoma (HCC). METHODS: Clinical data of the HCC patients without regional lymph node involvement or distant metastasis who received PBT at this institution between 2014 and 2017 were reviewed. A total of 43 patients were included. Tumor regression pattern after PBT were examined on the basis of follow-up duration. The variables were compared between patients with and without early tumor regression (ETR). RESULTS: The median follow-up duration was 40 months (range, 9-62 months). The cumulative overall survival rate at 6 months, 1 years and 5 years was 100%, 88.4%, 63.4%, respectively. Child-Pugh class A, local tumor control (LTC), complete response (CR), and ETR were significantly associated with overall survival (p < 0.05 each). Of 43 patients, 25 patients (58.1%) reached CR in the PBT-irradiated region. Twelve patients (27.9%) had a partial response and 3 patients (7.0%) had a stationary disease. Three patients (7.0%) developed in-field progression. The LTC rate at 5 years was 93.0%. Of the 25 patients who achieved a CR in the PBT-irradiated region, the median time to CR was 5 months (range, 1-19 months). Twenty-two patients (51.2%) showed ETR of the HCC, while 21 patients (48.8%) showed non-ETR. A significant association was observed between ETR and CR of the HCC after PBT (p < 0.001). CONCLUSION: The post-PBT MRI follow-up at 3 months is helpful for monitoring therapeutic response. ETR of the HCC predicted a higher rate of CR and was associated with overall survival, which provides more accurate clinical management.
Authors: Awalpreet S Chadha; Jillian R Gunther; Cheng-En Hsieh; Maureen Aliru; Lakshmi S Mahadevan; Bhanu P Venkatesulu; Christopher H Crane; Prajnan Das; Joseph M Herman; Eugene J Koay; Cullen Taniguchi; Emma B Holliday; Bruce D Minsky; Yelin Suh; Peter Park; Gabriel Sawakuchi; Sam Beddar; Bruno C Odisio; Sanjay Gupta; Evelyne Loyer; Harmeet Kaur; Kanwal Raghav; Milind M Javle; Ahmed O Kaseb; Sunil Krishnan Journal: Radiother Oncol Date: 2019-01-16 Impact factor: 6.280
Authors: Xiaochun Wang; Sunil Krishnan; Xiaodong Zhang; Lei Dong; Tina Briere; Christopher H Crane; Mary Martel; Michael Gillin; Radhe Mohan; Sam Beddar Journal: Med Dosim Date: 2008 Impact factor: 1.482
Authors: Nina N Sanford; Jennifer Pursley; Bridget Noe; Beow Y Yeap; Lipika Goyal; Jeffrey W Clark; Jill N Allen; Lawrence S Blaszkowsky; David P Ryan; Cristina R Ferrone; Kenneth K Tanabe; Motaz Qadan; Christopher H Crane; Eugene J Koay; Christine Eyler; Thomas F DeLaney; Andrew X Zhu; Jennifer Y Wo; Clemens Grassberger; Theodore S Hong Journal: Int J Radiat Oncol Biol Phys Date: 2019-01-23 Impact factor: 7.038
Authors: Guillaume Oldrini; Andres Huertas; Sophie Renard-Oldrini; Hélène Taste-George; Guillaume Vogin; Valérie Laurent; Julia Salleron; Philippe Henrot Journal: PLoS One Date: 2017-04-25 Impact factor: 3.240